The 9 analysts offering 12-month price forecasts for Y-mAbs Therapeutics, Inc have a median target of 48.00, with a high estimate of 52.00 and a low estimate of 40.00. The median estimate represents a +37.10% increase from the last price of 35.01.
The current consensus among 10 polled investment analysts is to Buy stock in Y-mAbs Therapeutics, Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.69
Reporting Date Aug 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.